Clinical Trials Logo

Nephritis, Hereditary clinical trials

View clinical trials related to Nephritis, Hereditary.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03749447 Terminated - Clinical trials for Chronic Kidney Diseases

An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)

EAGLE
Start date: March 8, 2019
Phase: Phase 3
Study type: Interventional

This extended access study will assess the long-term safety and tolerability of bardoxolone methyl in qualified patients with chronic kidney disease (CKD) who previously participated in one of the qualifying clinical studies with bardoxolone methyl. Patients will remain in the study until bardoxolone methyl is available through commercial channels or until patient withdrawal, whichever is sooner.

NCT ID: NCT02855268 Terminated - Alport Syndrome Clinical Trials

Study of Lademirsen (SAR339375) in Patients With Alport Syndrome

HERA
Start date: November 2, 2019
Phase: Phase 2
Study type: Interventional

Primary Objectives: - To assess the efficacy of lademirsen (SAR339375) in reducing the decline in renal function. - To assess the safety and tolerability of lademirsen (SAR339375) in participants with Alport syndrome. Secondary Objectives: - To assess plasma pharmacokinetic (PK) parameters of the parent compound and its active major metabolite. - To assess the potential formation of anti-drug antibodies (ADAs) following administration of lademirsen (SAR339375). - To assess the pharmacodynamic effect of lademirsen (SAR339375) on miR-21 and on changes in renal injury and function biomarkers.

NCT ID: NCT02718027 Terminated - Clinical trials for Nephritis, Hereditary

Biomarker for Alport Syndrome (BioAlport)

BioAlport
Start date: August 20, 2018
Phase:
Study type: Observational

International, multicenter, observational, longitudinal monitoring study to identify biomarker/s for Alport syndrome and to explore the clinical robustness, specificity, and long-term variability of these biomarker/s